(NASDAQ: INVA) Innoviva's forecast annual revenue growth rate of 6.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Innoviva's revenue in 2026 is $420,690,000.On average, 7 Wall Street analysts forecast INVA's revenue for 2026 to be $33,167,437,538, with the lowest INVA revenue forecast at $30,917,746,869, and the highest INVA revenue forecast at $35,510,127,231. On average, 7 Wall Street analysts forecast INVA's revenue for 2027 to be $36,436,427,031, with the lowest INVA revenue forecast at $31,465,407,786, and the highest INVA revenue forecast at $40,330,576,629.
In 2028, INVA is forecast to generate $36,619,472,729 in revenue, with the lowest revenue forecast at $34,614,089,019 and the highest revenue forecast at $38,306,002,644.